Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Very strong 2023: Double-digit growth for sales and Core Oplnc for the quarter and full year Met/exceeded all strategic, operational and innovation targets: Including successful Sandoz spin-off; 10 positive Ph3 readouts with significant sales potential Confident for 2024 and mid-term guidance of 5% cc sales CAGR 2023-28, -40%+ margin by 2027 □ NOVARTIS Reimagining Medicine Novartis Q4 Results | January 31, 2024 34

View entire presentation